Literature DB >> 20680807

FcγRs in health and disease.

Falk Nimmerjahn1, Jeffrey V Ravetch.   

Abstract

Genetic defects affecting the humoral immune response and especially the production of antibodies of the immunoglobulin G (IgG) isotype result in a heightened susceptibility to infections. Studies over the last years have demonstrated the crucial role of Fc-receptors for IgG (FcγRs) widely expressed on innate immune effector cells in mediating the protective function of IgG. During the last years, additional ligands interacting with FcγRs as well as additional receptors binding to IgG glycosylation variants have been identified. In this review, we discuss how the interaction of these different ligands with classical and novel Fcγ-receptors influences the immune response and which strategies microorganisms have developed to prevent them.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20680807     DOI: 10.1007/82_2010_86

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  67 in total

1.  Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement.

Authors:  Fubin Li; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-20       Impact factor: 11.205

2.  Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins.

Authors:  Hicham Bouhlal; Denis Martinvalet; Jean-Luc Teillaud; Catherine Fridman; Michel D Kazatchkine; Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2014-04-01       Impact factor: 8.317

3.  Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

Authors:  Elizabeth L McMichael; Nicholas B Courtney; Megan C Duggan; Robert Wesolowski; Dionisia Quiroga; Sri Vidya Kondadasula; Lakhvir S Atwal; Neela Bhave; Eric Luedke; Alena Cristina Jaime-Ramirez; Amanda R Campbell; Xiaokui Mo; John C Byrd; William E Carson Iii
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

Review 4.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

5.  Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

Authors:  Frederick W Jacobsen; Riki Stevenson; Cynthia Li; Hossein Salimi-Moosavi; Ling Liu; Jie Wen; Quanzhou Luo; Kristine Daris; Lynette Buck; Sterling Miller; Shu-Yin Ho; Wei Wang; Qing Chen; Kenneth Walker; Jette Wypych; Linda Narhi; Kannan Gunasekaran
Journal:  J Biol Chem       Date:  2016-12-19       Impact factor: 5.157

6.  Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect.

Authors:  David J DiLillo; Jeffrey V Ravetch
Journal:  Cell       Date:  2015-05-11       Impact factor: 41.582

7.  Anti-peptidoglycan antibodies and Fcγ receptors are the key mediators of inflammation in Gram-positive sepsis.

Authors:  Dawei Sun; Brent Raisley; Marybeth Langer; Janaki K Iyer; Vidya Vedham; Jimmy L Ballard; Judith A James; Jordan Metcalf; K Mark Coggeshall
Journal:  J Immunol       Date:  2012-07-18       Impact factor: 5.422

Review 8.  Intravenous immunoglobulin therapy: how does IgG modulate the immune system?

Authors:  Inessa Schwab; Falk Nimmerjahn
Journal:  Nat Rev Immunol       Date:  2013-02-15       Impact factor: 53.106

9.  Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Authors:  Silvie Van den Hoecke; Katrin Ehrhardt; Annasaheb Kolpe; Karim El Bakkouri; Lei Deng; Hendrik Grootaert; Steve Schoonooghe; Anouk Smet; Mostafa Bentahir; Kenny Roose; Michael Schotsaert; Bert Schepens; Nico Callewaert; Falk Nimmerjahn; Peter Staeheli; Hartmut Hengel; Xavier Saelens
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

Review 10.  With or without sugar? (A)glycosylation of therapeutic antibodies.

Authors:  Dmitrij Hristodorov; Rainer Fischer; Lars Linden
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.